Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community ...

ACADIA Pharmaceuticals (NASDAQ: ACAD) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates ...

We have a conviction buy rating on Acadia Pharmaceuticals' common stock (price target of $47.57 based on sum-of-the parts DCF method). The company is also an attractive acquisition target.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed ...

ACADIA Pharmaceuticals shares are trading lower by 4.11% during Tuesday's session. The company appointed Catherine Owen Adams as CEO. The next correction is closer than you think. Find out how Tom ...

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.